SecBot SecBot
8-K ·Filed May 18, 2026

MIRM

Mirum Pharmaceuticals, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-228902
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ◆ Mixed

The refinancing is credit-neutral to slightly positive: it removes a nearer-term convertible maturity, extends debt duration, and fixes a low or zero coupon. However, the absolute debt load increased meaningfully, and the new notes are convertible at only a 30% premium, implying potential share dilution of up to ~3% in a 'Make-Whole' scenario. Watch for hedge unwinds by note exchange counterparties (the filing acknowledges this risk). The net effect is a manageable but not transformative balance sheet extension.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$95.65
T+0 close · May 18, 2026 · via day close
Latest settled
+3.26%
T+60 · $98.77
Vs SPY
−3.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $95.65entry
  2. T+1 · 6mo ago +1.36%α +0.32% · $96.95
  3. T+5 · 6mo ago +1.76%α −0.54% · $97.33
  4. T+20 · 5mo ago +6.68%α +5.70% · $102.04
  5. T+60 · 3mo ago +3.26%α −3.03% · $98.77

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mirum issued $690.0M of 0.00% convertible senior notes due 2032, including the full $90M greenshoe. In privately negotiated concurrent note exchange transactions, the company will use ~$475M of net proceeds and issue 3,220,529 shares of common stock to exchange ~$237.2M of its existing 4.00% convertible notes due 2029. Net proceeds after all expenses are estimated at ~$671.6M. The capital structure refinancing extends maturities, eliminates a near-term convert overhang, and provides balance sheet flexibility. However, the amount of absolute debt has increased substantially, and the new notes carry contingent dilution potential of up to 6.46M shares (6.4% on the current share base).

Key Financial Metrics

Offering Size
$690.0M

Key Facts

  • $690.0M aggregate principal of 0.00% convertible senior notes due 2032 issued ($600M base + $90M greenshoe exercised).
  • Initial conversion rate of 7.1971 shares per $1,000 principal, implying a conversion price of ~$138.94, a ~30% premium over the $106.88 closing price on pricing date.
  • ~$475M of net proceeds + 3,220,529 shares of common stock will be used to exchange ~$237.2M of the outstanding 4.00% convertible notes due 2029.
  • Net proceeds estimated at ~$671.6M after underwriting discounts and expenses.
  • Notes are senior unsecured, mature June 1, 2032, and cannot be redeemed before June 6, 2029.
  • If a 'Make-Whole Fundamental Change' occurs, the conversion rate can be increased by up to 2.1591 shares (max rate 9.3562 shares/$1,000) during a defined period.
  • Issuance of 3,220,529 shares in the note exchange transactions represents ~3.4% dilution on a ~95M share base (authorized share count not disclosed in filing).

Financial Impact

$690.0 million in new debt raised; ~$237.2 million of existing 2029 convertibles eliminated; net debt increase of ~$452.8 million. The exchange portion is executed with $475M cash + 3.22M shares (market value ~$344M at $106.88).

total debtdilutionmaturity profileinterest expense

Risk Factors

  • Potential near-term selling pressure from hedge unwinds by note exchange counterparties buying MIRM stock/derivatives.
  • Dilution overhang: up to 6.46M shares (6.4% of current float) issuable upon conversion at the max conversion rate.
  • The new notes are senior unsecured, increasing the company's leverage profile.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-228902
Document: d113366d8k.htm0001193125-26-228902
Document: d113366dex992.htm0001193125-26-228902
Document: d113366dex991.htm0001193125-26-228902
Document: 0001193125-26-228902-index-headers.html0001193125-26-228902
Document: 0001193125-26-228902-index.html0001193125-26-228902
Document: 0001193125-26-228902.txt0001193125-26-228902

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026